Matthew Venezia's questions to Capricor Therapeutics Inc (CAPR) leadership • Q2 2025
Question
Matthew Venezia asked about turnover on the FDA review team and its potential impact, and also inquired about the company's expected expense run rate into 2026.
Answer
CEO Linda Marbán stated they will have more clarity on the FDA team after their meeting but stressed that the data's strength should transcend any personnel changes. CFO AJ Bergmann indicated that the expense profile will shift upon regulatory clarity, with potential capital injections from a PRV sale and milestone payments funding commercial launch activities.